Irinotecan Hcl Aqvida

Irinotecan Hydrochloride, the active ingredient in Irinotecan Hcl Aqvida, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed to treat colorectal cancer, including metastatic disease, in adult patients.

GNH USA supplies Irinotecan Hcl Aqvida as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Hydrochloride is used in oncology to target colorectal cancer and related disease states.

Colorectal cancer: improves response rates when combined with other chemotherapeutic agents. Metastatic colorectal cancer: provides therapeutic benefit in first‑line or later‑line regimens. Advanced colorectal cancer: used as part of combination therapy to extend progression‑free survival.

Irinotecan Hydrochloride may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require supportive care. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may be managed with anti‑emetics. - Fatigue: general tiredness experienced during treatment. - Alopecia: hair loss that is usually reversible. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Severe neutropenic infection: febrile neutropenia requiring immediate medical attention. - Life‑threatening diarrhea: may lead to dehydration and electrolyte imbalance. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Cardiac toxicity: rare cases of arrhythmia or myocardial ischemia.

When using Irinotecan Hydrochloride, clinicians should consider several safety measures.

Dose adjustment: modify dose in patients with hepatic impairment. Monitoring: perform regular complete blood counts and liver function tests. Hydration: ensure adequate fluid intake to mitigate diarrhea risk. Drug interactions: avoid concurrent use with strong CYP3A4 inhibitors. Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan Hydrochloride can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - High‑dose irinotecan with other topoisomerase I inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea. - Immunosuppressants (e.g., corticosteroids): increase infection susceptibility.